Overview

  • Product nameAnti-BRCA2 antibody
    See all BRCA2 primary antibodies
  • Description
    Rabbit polyclonal to BRCA2
  • Tested applicationsSuitable for: WB, IPmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Chimpanzee, Rhesus monkey, Gorilla, Orangutan
  • Immunogen

    Synthetic peptide, corresponding to a region within amino acids 450-500 of Human BRCA2 using the numbering given in entry NP_000050.1.

  • Positive control
    • Whole cell lysate from 293T, HeLa and Jurkat cells

Properties

Applications

Our Abpromise guarantee covers the use of ab123491 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/2000 - 1/10000. Predicted molecular weight: 384 kDa.
IP Use at 2-10 µg/mg of lysate.

Target

  • FunctionInvolved in double-strand break repair and/or homologous recombination. Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. May participate in S phase checkpoint activation. Binds selectively to ssDNA, and to ssDNA in tailed duplexes and replication fork structures.
  • Tissue specificityHighest levels of expression in breast and thymus, with slightly lower levels in lung, ovary and spleen.
  • Involvement in diseaseDefects in BRCA2 are a cause of susceptibility to breast cancer (BC) [MIM:114480]. A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.
    Defects in BRCA2 are the cause of pancreatic cancer type 2 (PNCA2) [MIM:613347]. It is a malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.
    Defects in BRCA2 are a cause of susceptibility to breast-ovarian cancer familial type 2 (BROVCA2) [MIM:612555]. A condition associated with familial predisposition to cancer of the breast and ovaries. Characteristic features in affected families are an early age of onset of breast cancer (often before age 50), increased chance of bilateral cancers (cancer that develop in both breasts, or both ovaries, independently), frequent occurrence of breast cancer among men, increased incidence of tumors of other specific organs, such as the prostate.
    Defects in BRCA2 are the cause of Fanconi anemia complementation group D type 1 (FANCD1) [MIM:605724]. It is a disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair.
    Defects in BRCA2 are a cause of glioma type 3 (GLM3) [MIM:613029]. Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.
  • Sequence similaritiesContains 8 BRCA2 repeats.
  • Post-translational
    modifications
    Phosphorylated by ATM upon irradiation-induced DNA damage.
    Ubiquitinated in the absence of DNA damage; this does not lead to proteasomal degradation. In contrast, ubiquitination in response to DNA damage leads to proteasomal degradation.
  • Information by UniProt
  • Database links
  • Alternative names
    • BRCA 2 antibody
    • BRCA1/BRCA2 containing complex subunit 2 antibody
    • Brca2 antibody
    • BRCA2, DNA repair associated antibody
    • BRCA2_HUMAN antibody
    • BRCC 2 antibody
    • BRCC2 antibody
    • Breast and ovarian cancer susceptibility gene early onset antibody
    • breast and ovarian cancer susceptibility protein 2 antibody
    • Breast cancer 2 early onset antibody
    • Breast Cancer 2 tumor suppressor antibody
    • Breast cancer susceptibility protein BRCA2 antibody
    • Breast cancer type 2 susceptibility protein antibody
    • BROVCA2 antibody
    • FACD antibody
    • FAD 1 antibody
    • FAD antibody
    • FAD1 antibody
    • FANCB antibody
    • FANCD 1 antibody
    • FANCD antibody
    • FANCD1 antibody
    • FANCD1 gene antibody
    • Fanconi anemia complementation group D1 antibody
    • Fanconi anemia group D1 protein antibody
    • GLM3 antibody
    • mutant BRCA2 antibody
    • OTTHUMP00000018803 antibody
    • OTTHUMP00000042401 antibody
    • PNCA2 antibody
    • XRCC11 antibody
    see all

Anti-BRCA2 antibody images

  • All lanes : Anti-BRCA2 antibody (ab123491) at 0.1 µg/ml

    Lane 1 : Whole cell lysate from HeLa at 50 µg/ml
    Lane 2 : Whole cell lysate from HeLa at 15 µg/ml
    Lane 3 : Whole cell lysate from 293T at 50 µg/ml
    Lane 4 : Whole cell lysate from Jurkat at 50 µg/ml

    Developed using the ECL technique

    Predicted band size : 384 kDa


    Exposure time : 10 minutes
  • Detection of Human BRCA2 by Immunoprecipitation from HeLa whole cell lysate (1 mg for IP, 20% of IP loaded), using ab123491 at 6 µg/mg lysate.
    Subsequent Western blot detection used ab123491 at 1 µg/ml.
    Detection: Chemiluminescence with an exposure time of 10 seconds.

References for Anti-BRCA2 antibody (ab123491)

This product has been referenced in:
  • Wali N  et al. Centrosomal BRCA2 is a target protein of membrane type-1 matrix metalloproteinase (MT1-MMP). Biochem Biophys Res Commun 443:1148-54 (2014). Read more (PubMed: 24384087) »
  • Barclay SS  et al. Systems biology analysis of Drosophila in vivo screen data elucidates core networks for DNA damage repair in SCA1. Hum Mol Genet N/A:N/A (2013). Mouse . Read more (PubMed: 24179173) »

See all 2 Publications for this product

Product Wall

Application Immunocytochemistry/ Immunofluorescence
Sample Human Cell (HeLa Cells (Cervical Cancer))
Permeabilization Yes - 0.5% Triton X-100 in PBS
Specification HeLa Cells (Cervical Cancer)
Blocking step BSA as blocking agent for 45 minute(s) · Concentration: 3% · Temperature: 37°C
Fixative Paraformaldehyde
Username

Abcam user community

Verified customer

Submitted Aug 04 2015

Application Western blot
Loading amount 40 µg
Gel Running Conditions Reduced Denaturing (6%)
Sample Human Cell lysate - whole cell (HeLa cell line)
Specification HeLa cell line
Blocking step BSA as blocking agent for 45 minute(s) · Concentration: 5% · Temperature: 23°C
Username

Abcam user community

Verified customer

Submitted Dec 12 2013

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"